BMO Capital Markets Reaffirms “Outperform” Rating for Acrivon Therapeutics (NASDAQ:ACRV)
BMO Capital Markets reaffirmed their outperform rating on shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) in a report issued on Monday morning, Benzinga reports. They currently have a $28.00 price objective on the stock, up from their previous price objective of $25.00. Several other research analysts also recently issued reports on ACRV. Piper Sandler […]
20 Sep 06:58 · The Markets Daily